home · filing · 0001376339-23-000055
8-K
filed July 5, 2023, 7:59 PM ET
ticker MDXG
CIK 0001376339
leadership
confidence high
sentiment neutral
materiality 0.60
MiMedx appoints Doug Rice as CFO; Peter Carlson resigns effective July 5, 2023
MIMEDX GROUP, INC.
Doug Rice, former CFO of Orthofix Medical, named CFO effective July 5, 2023.
Peter Carlson resigned as CFO effective same date.
Rice receives base salary of $540,000 and target cash bonus of 60% of base.
Inducement grants: 162,000 PSUs (3-yr performance), 97,200 RSUs (3-yr vest), 94,000 options (4-yr vest).
Rice brings experience from Orthofix, Vision Source, McAfee; is a CPA and MBA.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Doug Rice
Chief Financial Officer
MDXG ·
MIMEDX GROUP, INC.
Effective 2023-07-05
Filed July 5, 2023, 7:59 PM ET
Doug Rice has been appointed to serve as Chief Financial Officer of the Company, effective on July 5, 2023.
Departed
Peter Carlson
Chief Financial Officer
MDXG ·
MIMEDX GROUP, INC.
Effective 2023-07-05
Successor Doug Rice
Filed July 5, 2023, 7:59 PM ET
Peter Carlson submitted his resignation as Chief Financial Officer of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Doug Rice was appointed as Chief Financial Officer at MIMEDX GROUP, INC..
Action appointed
Role Chief Financial Officer
Exact text from the filing
Doug Rice has been appointed to serve as Chief Financial Officer of the Company, effective on July 5, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Carlson resigned as Chief Financial Officer at MIMEDX GROUP, INC..
Action resigned
Role Chief Financial Officer
Exact text from the filing
Peter Carlson submitted his resignation as Chief Financial Officer of the Company.
View on SEC.gov
Source: SEC EDGAR
accession 0001376339-23-000055
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.